EMA Highlights: New medicines granted EU approval
by Gary Finnegan: The European Medicines Agency (EMA) has recommended approval of several new medicines.
by Gary Finnegan: The European Medicines Agency (EMA) has recommended approval of several new medicines.
by Gary Finnegan – Medicines regulators have pledged closer transatlantic cooperation on medicine safety, building on earlier commitments to join forces on clinical trial site inspections.
by Gary Finnegan – The European drug regulator has given a paediatric-use marketing authorisation (PUMA) for Hemangiol to treat proliferation of infantile haemangioma.
by Bruce Sylvester: Ongoing statin treatment appears to prevent delirium in critically ill patients who had taken a statin prior to hospitalization, researchers reported online on Jan. 17,… read more.
by Bruce Sylvester: The antidepressant citalopram (Celexa/Cipramil, and generic) significantly reduces agitation among patients with Alzheimer’s disease, researchers reported in the Feb. 19, 2014 issue of JAMA/Journal of… read more.
by Bruce Sylvester: The antidepressant citalopram (Celexa/Cipramil, and generic) significantly reduces agitation among patients with Alzheimer’s disease, researchers reported in the Feb. 19, 2014 issue of JAMA/Journal of… read more.
by Bruce Sylvester: Topiramate, an FDA-approved anticonvulsant drug which had been shown to reduce drinking in patients committed to complete abstinence, appears to help problem drinkers whose want… read more.
“Despite already being rolled-out in many countries, our study is the first to look at the feasibility of the Xpert test in a real-life clinical setting in southern… read more.
Exacerbation severity in patients with chronic obstructive pulmonary disease (COPD) can be reliably assessed with the COPD Assessment Test™ (CAT), according to a new study from the UK.
Researchers in the U.K. report that non-restorative sleep is the strongest, independent predictor of widespread pain onset among adults over the age of 50.
Effects evaluated in new study published in PAIN. Poorly managed pain in the neonatal intensive care unit has serious short- and long-term consequences, causing physiological and behavioural instability… read more.
A recent pharmacokinetic study with buprenorphine transdermal patches showed similar systemic exposures of buprenorphine in subjects aged 75 and 50–60 years. The current prospective, open-label study aimed to… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.